Eisai Co., Ltd. (エーザイ株式会社) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[3]
History
Nihon Eisai Co. Ltd. was established in 1941.[4] In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[5] The American subsidiary of the company, Eisai Inc., was established in 1995.[6]
On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (